R & D and innovation
We pay attention to research and development innovation. While providing products and services for scientists of Chinese universities, research institutes, laboratories, and pharmaceutical companies, Yuhan adheres to innovation and pursuit of excellence. Research and development of new antitumor small molecular drugs, research on salt and crystal screening of small molecular drugs, and key intermediate process development and optimization. At present, the small molecular anti -osteomaicoma (PIM kinase inhibitors) in the research has initially selected a new type of high -active candidate drugs that are better than known clinical drugs, and subsequent research is continuing. The key intermediates of PEXIDARTINIB developed in the early stage of PEXIDARTINIB have been completed. We look forward to accelerating the process of listing of partners' drugs, helping to develop new drug research and development, and benefit human health.
Research and development of new antitumor small molecular drugs |
Study on salt and crystal screening of small molecular drugs |
Development and research of key intermediates |
|
New discoveries
C-met novel inhibitor PIM inhibitors PI3K inhibitor IDO inhibitors |
